PCSK9 as a Biomarker and Therapeutic Target for Anthracycline Cardiotoxicity Prevention: Recent Advancements and Future Perspectives.
Saved in:
| Title: | PCSK9 as a Biomarker and Therapeutic Target for Anthracycline Cardiotoxicity Prevention: Recent Advancements and Future Perspectives. |
|---|---|
| Authors: | Gadelmawla AF; Department of Medicine, Menoufia University, Menoufia, Egypt., Alkuwaiti MA; Department of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Eastern Province, Saudi Arabia., Alsubaiei AA; Department of Medicine, Kuwait Institute for Medical Specializations, Kuwait City, Kuwait., AlSejari NY; Department of Medicine, Kuwait Institute for Medical Specializations, Kuwait City, Kuwait., Alharran AM; Department of Medicine, College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain., Abdul-Hafez HA; Department of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine., Mohamed AE; Department of Internal Medicine, One Brooklyn Health Hospital, Brooklyn, NY., Frishman WH; Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY., Aronow WS; Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY. |
| Source: | Cardiology in review [Cardiol Rev] 2026 May 08. Date of Electronic Publication: 2026 May 08. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9304686 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-4683 (Electronic) Linking ISSN: 10615377 NLM ISO Abbreviation: Cardiol Rev Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
